drugset / Trial / NCT05063149

Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.

NCT05063149 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The primary objective of this study is to reduce respiratory tract infections and wheezing in moderate-late preterms in the first years of life by bacterial lysate administration. Next to determine the correlation of biological markers with respiratory symptoms, immune protection and treatment effect.

Timeline

Start
2022-03-18
Primary completion
2029-12
Completion
2030-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Broncho-Vaxom Other / unclassified 3.5 mg —